
May 12 (Reuters) - Apogee Therapeutics Inc APGE.O:
APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS FROM THE PHASE 1B TRIAL OF APG808, ITS NOVEL HALF-LIFE EXTENDED IL-4RΑ ANTIBODY, IN PATIENTS WITH MILD-TO-MODERATE ASTHMA
APOGEE THERAPEUTICS INC: APG808 WAS WELL TOLERATED WITH A FAVORABLE SAFETY PROFILE CONSISTENT WITH ANTI-IL-4RΑ CLASS
APOGEE THERAPEUTICS: APG808 SHOWED POTENTIAL FOR DURABLE DISEASE CONTROL IN ASTHMA WITH SUSTAINED FENO DECREASE FROM BASELINE OF 50% AT 12 WEEKS